The portfolio of the Company includes two ophthalmology assets that have been approved by the U.S. Food and Drug Administration (FDA), VYZULTATM (latanoprostene bunod ophthalmic solution), 0.024%, licensed worldwide to Bausch + Lomb, which was approved by the FDA in November 2017, and ZERVIATETM (cetirizine ophthalmic solution, 0.24%, formerly AC-170), approved by the FDA in May 2017 and licensed in the US to Eyevance Pharmaceuticals LLC. The commercialization in the US through partners is planned for VYZULTATM by end 2017 and for ZERVIATETM in late 2018. In addition, Nicox’ product candidate pipeline features clinical-stage assets based both on its proprietary nitric oxide (NO)-donating technology, and on the repurposing of existing molecules as well as a next-generation of stand-alone nitric-oxide donors and exploratory novel NO-donating compounds with the potential to offer novel approaches to treat a range of ophthalmic conditions.
The Company’s strategy is to become a fully integrated pharmaceutical company focused on the discovery, development and commercialization of novel ophthalmology therapeutics. This includes the expansion of its ophthalmic product portfolio through internal discovery efforts based on our NO-donating research platform, the repurposing of established molecules and possible in-licensing activities or acquisitions of additional ophthalmic product candidates or products. Nicox, which is headquartered in Sophia Antipolis, France, was formed in 1996 and has been listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) since 1999. Nicox has research facilities in Bresso, Italy, and a U.S. office in Fort Worth, Texas.
Addressing a gap in the ophthalmic market
Certain areas, such as retinal conditions and dry eye, are expected to experience considerable growth due to a significant need for better treatments and diagnostic options. The ophthalmic market is currently dominated by large global pharmaceutical companies and much smaller national players. We see the opportunity for a targeted R&D organisation in ophthalmology. Our experienced team brings together a heritage of scientific, financial, business and corporate development expertise, strengthened by our own in-house research capabilities. Our route for growth is based on the confirmed potential of our proprietary NO-donating research platform, our other proprietary development assets and our partnered programs. We intend to develop our portfolio through outstanding international collaborations and internal focus on our proprietary developments.
IMS Health Analytics sales 2016
Partnerships accelerate the advancement of Nicox’s research and development activities, allowing us to share and build our expertise and endorse the company’s nitric oxide-donating research platform. The Company expects partnerships to continue to have a significant place in its future development both through the partnering of assets already advanced by Nicox and through allowing us to access innovative science from external sources. We are always interested in hearing about potential collaborations and seek partners with complementary strengths who share our values; do not hesitate to contact us if you share our passion for visible science.
Nicox is led by a team of experienced professionals whose combined expertise covers research, clinical development, regulatory interactions, finance, business and corporate development, alliance management and communication. This experience was acquired in leading pharmaceutical and biotech companies and the team includes Michele Garufi, one of Nicox’s co-founders.
Nicox is proud to present its Board of Directors, whose members are highly experienced in the pharmaceutical and biotech industry.